Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
LONDON - Ananda Pharma PLC (AQSE:ANA, OTC: ANANF) announced Monday it has completed the dosing phase of its Phase 1 pharmacokinetic study for MRX1 CBD, reaching the Last Participant, Last Dose milestone in the clinical trial conducted in Melbourne, Australia.
The study enrolled 19 healthy adult volunteers, evenly split between males and females, across two dosing cohorts to evaluate the pharmacokinetics, safety, and tolerability of MRX1 CBD in humans.
With the dosing phase now complete, the company will lock the database and begin data analysis. Ananda expects to report on safety and tolerability in Q4 2025, with the first draft clinical trial report anticipated in Q1 2026.
"Reaching Last Participant, Last Dose is an important milestone in our MRX1 development program," said Melissa Sturgess, Chief Executive Officer of Ananda Pharma. "I am particularly pleased that half the participants in the study were female."
The UK-based biopharmaceutical company is developing cannabidiol medicines to treat chronic conditions including endometriosis and chemotherapy-induced peripheral neuropathy. Data from this trial will be used for Federal Drug Administration regulatory filings and to inform future trial protocols.
The company noted that the database will now be locked with final readouts on track for delivery in Q1 2026.
Ananda Pharma is working with scientists and Key Opinion Leaders at the University of Edinburgh, according to the press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.